



REVIEW

Progress report on new antiepileptic drugs: A summary of the Tenth Eilat Conference (EILAT X)

Meir Bialer^{a,*}, Svein I. Johannessen^{b,c}, René H. Levy^d, Emilio Perucca^e, Torbjörn Tomson^f, H. Steve White^g

^a Institute for Drug Research, School of Pharmacy and David R. Bloom Center for Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel

^b The National Center for Epilepsy, Sandvika, Norway

^c Department of Pharmacology, Oslo University Hospital, Oslo, Norway

^d Department of Pharmaceutics and Neurological Surgery, University of Washington, Seattle, Washington, WA, USA

^e Clinical Pharmacology Unit, Department of Internal Medicine and Therapeutics, University of Pavia, and Institute of Neurology IRCCS C. Mondino Foundation, Pavia, Italy

^f Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden

^g Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT, USA

Received 23 June 2010; received in revised form 25 August 2010; accepted 12 September 2010

KEYWORDS

Antiepileptic drugs;
Drug development;
Epilepsy;
Pharmacology;
Clinical trials;
Conference

Summary The Tenth Eilat Conference on New Antiepileptic Drugs (AEDs)-EILAT X, took place in Eilat, Israel from the 25th to 29th of April 2010. About 200 basic scientists, clinical pharmacologists and neurologists from 25 countries attended the conference, whose main themes included learning from the past: Lessons learnt after 18 years of Eilat Conferences and Detecting assessing and preventing adverse effects of AEDs. Consistent with previous formats of this conference, a large part of the program was devoted to a review of AEDs in development, as well as updates on AEDs introduced since 1994. Like the previous EILAT (EILAT IX) manuscript, the current (EILAT X) manuscript focuses only on the preclinical and clinical pharmacology of AEDs that are currently in development. These include brivaracetam, carisbamate, 2-deoxy-glucose, ganaxolone, huperizine A, ICA-105665, NAX-5055, retigabine, perampanel, T-2007, valnoctamide and YK3089. Since the previous Eilat Conference (EILAT IX-2008) two new AEDs; eslicarbazepine acetate and lacosamide have been marketed and three new AEDs in development not included in the EILAT IX manuscript were added: ICA-105665, perampanel and valnoctamide. The CNS efficacy of these compounds in anticonvulsant animal models as well as other disease model systems are presented in [Tables 1 and 2](#) and their proposed mechanism of action at summarized in [Table 3](#).

© 2010 Elsevier B.V. All rights reserved.

* Corresponding author at: School of Pharmacy and David R. Bloom Centre for Pharmacy, Faculty of Medicine, Ein Karem, The Hebrew University of Jerusalem, 91120 Jerusalem, Israel. Tel.: +972 2 6758610; fax: +972 2 6757246.

E-mail address: bialer@md.huji.ac.il (M. Bialer).

Contents

Brivaracetam (ucb34714)	92
Introduction and rationale for development	92
Pharmacology	92
Toxicology	92
Clinical pharmacokinetics	92
Drug interactions	98
Efficacy data	98
Phase IIb studies	98
Phase III fixed-dose studies	99
Tolerability and adverse events	99
Ongoing clinical studies	99
Carisbamate (RWJ-333369)	100
Introduction and rationale for development	100
Pharmacology	100
Clinical pharmacokinetics	100
Drug interactions	101
Efficacy data	101
Tolerability and adverse events	102
Ongoing clinical studies	102
2-Deoxy-D-glucose	103
Introduction and rationale for development	103
Pharmacology	103
Glycolytic inhibition by 2-deoxy-D-glucose	103
Anticonvulsant profile in experimental models	103
Pharmacokinetics and cerebral uptake mechanisms	104
Toxicology	104
Planned studies	104
Ganaxolone	104
Introduction and rationale for development	104
Pharmacology	105
Toxicology	105
Animal pharmacokinetics	105
Clinical pharmacokinetics	105
Drug interactions	106
Efficacy data	106
Partial onset seizures in adults	106
Infantile spasms trial	106
Tolerability and adverse events	107
Partial onset seizures in adults	107
Infantile spasms	107
Huperzine A	107
Introduction and rational for development	107
Pharmacology	107
Anticonvulsant profile	107
Antinociceptive activity	108
Neuroprotection and cognitive enhancement	108
Mechanisms of action	108
Toxicology	108
Clinical pharmacokinetics	108
Drug interactions	108
Efficacy and tolerability	108
Ongoing and planned studies	108
ICA-105665	109
Introduction and rationale for development	109
Pharmacology	109
Anticonvulsant activity in animal models	109
Mechanism of action	109
Toxicology	109
Clinical pharmacokinetics	109
Drug interactions	110

Download English Version:

<https://daneshyari.com/en/article/3052492>

Download Persian Version:

<https://daneshyari.com/article/3052492>

[Daneshyari.com](https://daneshyari.com)